Quality of life and attention-deficit/hyperactivity disorder core symptoms a pooled analysis of 5 Non-US atomoxetine clinical trials

Journal of Clinical Psychopharmacology

Volumn 30, Issue 2, 2010, Pages 145-151

  Escobar, Rodrigo ^a   Schacht, Alexander ^b   Wehmeier, Peter M ^b   Wagner, Thomas ^b  

^a Medical Department   (Spain)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

ADHD RS; Atomoxetine; Child health and illness profile; Quality of life

Indexed keywords

ATOMOXETINE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; AVOIDANCE BEHAVIOR; CHILD HEALTH; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CANADA; CHILD; CLINICAL TRIALS AS TOPIC; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROPYLAMINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952121726     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181d21763     Document Type: Article

References (53)

1. Polanczyk G, Silva de Lima M, Lessa Horta B, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007; 164: 942-948. (Pubitemid 46972911)
2. Barkley RA, Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002; 63(suppl 12): 10-15.
3. Biederman. J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005; 366: 237-248.
4. Nijmeijer JS, Minderaa RB, Buitelaar JK, et al. Attention-deficit/ hyperactivity disorder and social dysfunctioning. Clin Psychol Rev. 2008; 28: 692-708. (Pubitemid 351374606)
5. Escobar R, Hervas A, Soutullo CA, et al. Attention-deficit/hyperactivity disorder: burdens of the disease according to subtypes in recently diagnosed children. Actas Esp Psiquiatr. 2008; 36: 285-294.
6. Johnston C, Mash EJ. Families of children with attention-deficit/ hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev. 2001; 4: 183-207. (Pubitemid 33610771)
7. Sawyer MG, Whaites L, Rey JM, et al. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry. 2002; 41: 530-537. (Pubitemid 38338131)
8. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004; 114: e541-e547. (Pubitemid 41655750)
9. Matza LS, Rentz AM, Secnik K, et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2004; 25: 166-174. (Pubitemid 38960833)
10. Escobar R, Soutullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005; 116: e364-e369. (Pubitemid 44336649)
11. Riley AW, Spiel G, Coghill D, et al. Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry. 2006; 15(suppl 1): i38-i45.
12. Banaschewski T, Roessner V, Dittmann RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004; 13(suppl 1): 102-116.
13. Becker K, Wehmeier PM, Schmidt MH. The Noradrenergic Transmitter System in ADHD. Principles and Implications for Treatment. Stuttgart, Germany: Thieme; 2006.
14. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001; 108: e83-e91.
15. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. A J Psychiatry. 2002; 159: 1896-1901. (Pubitemid 35283256)
16. Spencer T, Heiligenstein JH, Biederman J. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002; 63: 1140-1147. (Pubitemid 36084059)
17. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004; 114: e1-e8.
18. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, NY: Guilford.; 1998.
19. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord,. 2001; 5: 39-47.
20. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education and Welfare; 1976: 218-222.
21. Rapoport J, Conners CK. Clinical global impressions. In; Rapoport J, Conners CK, eds. Rating Scales and Assessment Instruments for Use in Pediatric Psychopharmacology Research (Special Issue). Psychopharmacol Bull. 1985; 21(4): 839-843.
22. Buitelaar JK, Danckaerts M, Gillberg C, et al. A prospective, multi-center, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2004; 13: 249-257. (Pubitemid 39279157)
23. Perwien AR, Faries DE, Kratochvil CJ, et al. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr. 2004; 25: 264-271.
24. Matza LS, Stoeckl MN, Shorr JM, et al. Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. Expert Rev Pharmacoeconomics Outcomes Res. 2006; 6: 379-390. (Pubitemid 44304748)
25. Brown RT, Perwien A, Faries DE, et al. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila). 2006; 45: 819-827. (Pubitemid 44570029)
26. Perwien AR, Kratochvil CJ, Faries DE, et al. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol. 2006; 6: 713-824.
27. Prasad S, Hapin V, Poole L, et al. A multicentre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007; 23: 379-394. (Pubitemid 46333386)
28. Wehmeier PM, Dittmann RW, Schacht A, et al. Effectiveness of atomoxetine in children with attention-deficit/hyperactivity disorder and quality of life as perceived by patients, parents and physicians in an open-label study. J Child Adolesc Psychopharmacol. 2007; 17(6): 813-830. (Pubitemid 351158598)
29. Wehmeier PM, Schacht A, Lehmann M, et al. Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/ hyperactivity disorder: findings from a patient, parent and physician perspective. Child Adolesc Psychiatry Mental Health. 2008; 2: 10 (published online).
30. Landgraf J, Abetz L, Ware J. Child Health Questionnaire (CHQ): A Users Manual. Boston, MA: Integrated Therapeutics Group; 1996.
31. Riley AW, Robertson J, Forrest CB, et al. Manual for the Child Health and Illness Profile-Child Edition (CHIP-CE™). Baltimore, MD: The Johns Hopkins University; 2001.
32. Riley AW, Coghill D, Forrest CB, et al. ADORE study group: validity of the health-related quality of life assessment in the ADORE study: parent report form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry. 2006b; 15(suppl 1): i63-i71. (Pubitemid 46009498)
33. Hatpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005; 90(suppl I): i2-i7.
34. Hakkart-van Roijen L, Zwirs BWC, Bouwmans C, et al. Societal cost and quality of life of children suffering from attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 2007; 16: 316-326. (Pubitemid 47305457)
35. Yang P, Hsu HY, Chiou SS, et al. Health-related quality of life in methylphenidate-treated children with attention-deficit/hyperactivity disorder: results from a Taiwanese sample. Aust NZ J Psychiatry. 2007; 41(12): 998-1004. (Pubitemid 350120829)
36. Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q. 2008; 79(2): 133-137.
37. Wallander JL, Schmitt M, Koot HM. Quality of life measurements in children and adolescente: issues, instruments, and applications. J Clin Psychol. 2001; 57: 571-585. (Pubitemid 32247040)
38. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999; 2: 113-127.
39. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000; 9: 887-900. (Pubitemid 32210183)
40. Schmidt LJ, Garratt AM, Fitzpatrick R. Child/parent-assessed population health outcome measures: a structured review. Child Health Care Dev. 2001; 28(3): 227-237. (Pubitemid 34823061)
41. Riley AW, Forrest CB, Starfield. B, et al. The parent report form of the CHIP-Child Edition: reliability and validity. Med Care. 2004; 42: 210-220.
42. Coghill D, Danckaerts M, Sonuga-Barke E, et al. ADHD European Guidelines Group. Practitioner review: quality of life in child mental health-conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009; 50: 544-561.
43. Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/ hyperactivity disorder. Curr Med Res Opin. 2009; 25: 2745-2754.
44. Dell'Agnello G, Maschiatto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian, study. Eur Neuropsychopharmacol. 2009; 19: 822-834.
45. Dickson R, Jackiewicz G, Khattak S, et al. Change in ADHD symptoms and functional outcomes in Canadian children during 3 months of atomoxetine treatment. Presented at: Canadian Academy of Child and Adolescent Psychiatry 27th Annual Conference; November 11-13, 2007; Montreal, Quebec, Canada.
46. Deleted in proof.
47. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004; 43: 896-904. (Pubitemid 38808495)
48. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010; 19: 83-105.
49. Buitelaar JK, Wilens TE, Zhang S, et al. Comparison of symptomatic versus functional changes in children and adolescente with ADHD during randomized, double-blind treatment with psychostimulants atomoxetine, or placebo. J Child Psychol Psychiatry. 2009; 50: 335-342.
50. Weiss M, Lee B, Turgay A, et al. Atomoxetine treatment: correlations of ADHD, academic, cognitive, and functional outcomes. Poster presented at: 57th Annual Meeting of the Canadian Psychiatric Association; November 1.5-18,2007; Montréal, Québec, Canada.
51. Newcorn JH, Kratochvil CJ, Allen. AJ, et al. Atomoxetine/ Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008; 165: 721-730.
52. Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder. A randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009; 18: 240-249.
53. Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009; 19: 253-263.